Global Tumour Ablation Market Outline
Tumour ablation is a minimally invasive surgical method which enables treats solid tumours in which special probes are used to freeze or burn cancers without the usual surgery. Tumour ablation method is guided by the help of CT scan, MRI Scan and ultrasound to locate and to position the needle probe into the tumour which requires a tiny hole of 3mm diameter to introduce the probe. When the probe is within cancer it is attached to a generator which burns and freezes cancer. Most common cancers that are treated by this method are lung cancers, renal cancer, and liver cancer.
Increasing in a number of cancer cases and rise in geriatric population are the major factors which are attributing for the growth of tumour ablation market. As per the WHO statistics, cancer accounts for 13% of deaths globally every year, moreover, 70% increase in cancer incidences is anticipated over the next couple of decades. The global geriatric population is anticipated to nearly double from 12% to 22% from 2015 to 2022. Furthermore, increase in the number of hospitals, ablation and surgical centers, less procedural costs associated with radiofrequency ablation tumour and advanced technologies in ablation devices, improved healthcare expenditure, growing awareness, and increased government support are the few more factors which expected to boost the growth of tumour ablation market globally. However, stringent regulatory framework, prolonged time of approvals for product launching and cost containment measures are expected to hamper the growth of tumour ablation market.
Tumour Ablation Market is segmented on basis of function, technology, application, end user and Geographical regions.
Based on the function, the global tumour ablation market is segmented
- Automated/Robotic ablation
- Conventional ablation devices
Based on the technology, The Global Tumour Ablation Market is segmented
- Hyperthermic ablation
- Radiofrequency ablation
- Microwave ablation
- Laser ablation
- Ultrasound ablation
Based on the application, the global tumour ablation market is segmented
- Primary lung cancer
- Metastatic diseases
- Pain palliation
Based on the end user, the global tumour ablation market is segmented
- Oncology institutes
- Diagnostic centres
Innovations in resources and technologies required in tumour ablation have provided an ample of opportunities for various pharma and electronics companies to work for the betterment of currently available technologies of tumour ablation. Innovations such as high intensity focussed ultrasound (HIFU), irreversible electroporation and image-guided procedures are rising demand for adaptation of tumour ablation. Moreover, increased focus on R&D investments, product developments, and launches, acquisitions, mergers, and collaborations are few strategies adopted by the players in the market. For exemplary, in 2016, Medtronic launchedBarrx360 express radiofrequency ablation balloon catheter to treat Barrett’s esophagus and in 2016 may, BTG Plc. has acquired Galil Medical, cryoablation systems, and needles manufacturer.
Tumour Ablation Market is segmented into North America, Asia-Pacific, Europe, and the Middle East & Africa, Latin America. North America holds the largest share in tumour ablation market followed by Europe owing to the high incidence and prevalence of major cancers such as liver, kidney, lung and bone metastasis, increase in inclination towards minimally invasive procedures for treating cancer, the rise in government funds for cancer research. According to the reports of American Cancer Society, annual cancer incidences in U.S are 300.2 per 100,000 people and 296.6 cases per 100,000 people in Canada. Asia Pacific is anticipated to show significant growth during the foresee period owing to large population pool, growing economic developments in countries like China and India and improved healthcare infrastructure.
Some of the players in tumour ablation market are Boston Scientific Corporation (U.S.), Angiodynamics, Inc. (U.S.), BTG International Ltd (UK), Healthtronics, Inc. (U.S.), Medtronic, Plc (U.S.), EDAP TMS S.A. (France), Mermaid Medical, Inc. (Denmark), Neuwave Medical, Inc. (U.S.), Sonacare Medical, LLC (U.S.) and Mesonix, Inc. (U.S.)
- In 2015 January, Medtronic acquired Covidien which has improved its product portfolio of tumour ablation products
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario